Company intelligence / Profile preview

AEON Biopharma, Inc.

Irvine, California, United Statesaeonbiopharma.com ↗

Ownership: Public · AEON
Development stage: Phase 2

Overview

AEON Biopharma is pursuing a 351(k) biosimilar regulatory pathway for ABP-450 (prabotulinumtoxinA) using BOTOX as the reference product. The company has aligned with the FDA on next steps and plans to conduct comparative analytical studies. A Phase 3 study in cervical dystonia is planned to demonstrate non-inferiority to BOTOX.

Therapeutic areas: Neurology
Modalities: Botulinum toxin complex (neurotoxin)
Industry: Biotech

Drug pipeline

1 asset

ABP-450

Phase 2

Indications: Cervical dystonia, Facial wrinkles, Upper limb spasticity, Chronic migraine

Partnerships

Daewoong (manufacturer)Evolus (markets the same toxin for cosmetic use as Jeuveau)

Financials

Market cap: $12.8M
Total revenue: $0
Enterprise value: $12.2M

Beyond the preview

Go deeper on AEON Biopharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEON Biopharma, Inc..

Explore the full profile